<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031872</url>
  </required_header>
  <id_info>
    <org_study_id>M19TGA</org_study_id>
    <nct_id>NCT04031872</nct_id>
  </id_info>
  <brief_title>LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)</brief_title>
  <official_title>MoTriColor: Phase I/II Study With LY3200882 Combined With Capecitabine in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and an Activated TGF-beta Signature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agendia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Niguarda Cà Granda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catalan Institute of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the&#xD;
      combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU&#xD;
      or capecitabine resistant CRC. Part II is designed to obtain proof of principle of the&#xD;
      LY3200882 plus capecitabine combination in patients with chemo-resistant CRC. The combination&#xD;
      of LY3200882 plus capecitabine will be given as second line therapy in the phase II part of&#xD;
      this study.&#xD;
&#xD;
      Patients with chemotherapy resistant activated TGF-β signature-like tumors will have received&#xD;
      a fluoropyrimidine (5FU or capecitabine) in the first line of chemotherapy, usually combined&#xD;
      with oxaliplatin and, depending upon local hospital preferences or national guidelines, also&#xD;
      bevacizumab, or cetuximab/panitumumab if the tumor is KRAS wild type. Addition of LY3200882&#xD;
      to capecitabine should thus result in reversal of unresponsiveness, which is the first step&#xD;
      in exploring this concept in the clinic. Capecitabine can be used as single agent in advanced&#xD;
      CRC and is thus attractive for this study concept. If proof of principle is achieved also&#xD;
      other tumor types can be explored with this genetic makeup, such as non-small cell lung&#xD;
      cancer (NSCLC) in second line of treatment after platinum doublet therapy in first line,&#xD;
      usually cisplatin/carboplatin-pemetrexed in non-squamous and&#xD;
      cisplatin/carboplatin-gemcitabine or cisplatin/carboplatin-paclitaxel in squamous type NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: The recommended phase 2 dose (RP2D) of galunisertib plus capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (phase II only)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LY3200882 in combination with chemotherapy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene alterations/expression profiles (e.g. baseline, relapse) in tumor tissue upon progression</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline molecular status of potential predictive markers of tumor response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (phase II only)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>TGF-beta activated colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TGF-beta activated advanced colorectal cancer with LY3200882 and capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3200882</intervention_name>
    <description>Combination treatment with LY3200882 and capecitabine</description>
    <arm_group_label>TGF-beta activated colorectal cancer</arm_group_label>
    <other_name>Capecitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological or cytological proof of CRC;&#xD;
&#xD;
          2. Disease progression or relapse upon at least one line of treatment for advanced CRC&#xD;
             with fluoropyrimidine containing chemotherapy as single agent or in combination&#xD;
             (combinations with oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab are&#xD;
             allowed);&#xD;
&#xD;
          3. Written documentation of activated TGF-β signature-like gene signature, as determined&#xD;
             by the validated assay of Agendia;&#xD;
&#xD;
          4. Age ≥ 18 years;&#xD;
&#xD;
          5. Able and willing to give written informed consent;&#xD;
&#xD;
          6. WHO performance status of ≤ 1;&#xD;
&#xD;
          7. LVEF ≥ 55%;&#xD;
&#xD;
          8. Able and willing to undergo blood sampling for PK and PD analysis;&#xD;
&#xD;
          9. Able and willing to undergo tumor biopsies before start, during treatment and at the&#xD;
             end of treatment&#xD;
&#xD;
         10. Life expectancy ≥ 3 months allowing adequate follow up of toxicity evaluation and&#xD;
             anti-tumor activity;&#xD;
&#xD;
         11. Evaluable disease according to RECIST 1.1 criteria (measurable disease for the phase&#xD;
             II part; evaluable disease is sufficient for the phase I part);&#xD;
&#xD;
         12. Minimal acceptable safety laboratory values&#xD;
&#xD;
               1. ANC of ≥ 1.5 x 109 /L&#xD;
&#xD;
               2. Platelet count of ≥ 100 x 109 /L&#xD;
&#xD;
               3. Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN, ALAT and ASAT ≤ 3.0 x&#xD;
                  ULN, or ALAT and ASAT ≤ 5 x ULN in patients with liver metastases&#xD;
&#xD;
               4. Renal function as defined by serum creatinine ≤1.5 x ULN&#xD;
&#xD;
               5. Creatinine clearance ≥ 50 ml/min (by Cockcroft-Gault formula or MDRD);&#xD;
&#xD;
         13. Negative pregnancy test (urine or serum) for female patients with childbearing&#xD;
             potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any treatment with investigational drugs within 30 days prior to receiving the first&#xD;
             dose of investigational treatment;&#xD;
&#xD;
          2. Known or suspected dihydropirimidine dehydrogenase deficit (Mutant for DPD*2A&#xD;
             genotype, 1236 GA genotype, 1679TG genotype and 2846A&gt;T genotype);&#xD;
&#xD;
          3. Symptomatic or untreated leptomeningeal disease;&#xD;
&#xD;
          4. Symptomatic brain metastasis. Patients previously treated or untreated for these&#xD;
             conditions that are asymptomatic in the absence of corticosteroid therapy are allowed&#xD;
             to enrol. Brain metastasis must be stable with verification by imaging (e.g. brain MRI&#xD;
             or CT (&lt;21 days before start of treatment) completed at screening demonstrating no&#xD;
             current evidence of progressive brain metastases). Patients are not permitted to&#xD;
             receive enzyme inducing anti-epileptic drugs or corticosteroids;&#xD;
&#xD;
          5. History of cardiac disease, including myocardial infarction within 6 months before&#xD;
             study entry, unstable angina pectoris, New York Heart Association Class III/IV&#xD;
             congestive heart failure, or uncontrolled hypertension, major cardiac abnormalities, a&#xD;
             predisposition for developing aneurysms including family history of aneurysms, Marfan&#xD;
             syndrome, bicuspid aortic valve, or evidence of damage to the large vessels of the&#xD;
             heart.&#xD;
&#xD;
          6. Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of oral LY3200882 (e.g., ulcerative diseases, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection);&#xD;
&#xD;
          7. Woman who are pregnant or breast feeding;&#xD;
&#xD;
          8. Radio- or chemotherapy within the last 2 weeks prior to receiving the first dose of&#xD;
             investigational treatment. Palliative radiation (1x 8Gy) is allowed;&#xD;
&#xD;
          9. Patients who have undergone any major surgery within the last 2 weeks prior to&#xD;
             starting study drug or who would not have fully recovered from previous surgery;&#xD;
&#xD;
         10. Active infection requiring systemic antibiotics or uncontrolled infectious disease;&#xD;
&#xD;
         11. Patients with a known history of hepatitis B or C or known Human Immunodeficiency&#xD;
             Virus HIV-1 or HIV-2 type patients;&#xD;
&#xD;
         12. Other severe, acute, or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration or that may interfere with the interpretation of study results&#xD;
             and, in the judgment of the investigator, would make the patient inappropriate for the&#xD;
             study;&#xD;
&#xD;
         13. Known hypersensitivity to one of the study drugs or excipients.&#xD;
&#xD;
         14. For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraceptive methods with a failure rate of &lt;1% per&#xD;
             year (when used consistently and correctly) during the treatment period and for at&#xD;
             least 90 days after the last dose of LY3200882 and/or capecitabine. More information&#xD;
             is available in section 5.2.4.&#xD;
&#xD;
         15. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures, and agreement to refrain from donating sperm, as defined in&#xD;
             section 5.2.4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Tabernero, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>VHIO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R Bernards, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R Salazar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S Siena, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>ONCG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Cervantes, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>INCLIVA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F Ciardello, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNINA2</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Bardelli, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNITO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S Tejpar, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neeltje Steeghs, MD, PhD</last_name>
    <phone>+310205129111</phone>
    <email>n.steeghs@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanne Huijberts, MD</last_name>
    <phone>+310205129111</phone>
    <email>s.huijberts@nki.nl</email>
  </overall_contact_backup>
  <link>
    <url>http://www.motricolor.eu</url>
    <description>Related info</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TGF- beta activated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

